Northwestern Mutual Wealth Management’s Theriva Biologics TOVX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25	Buy	+100	New	+$30	﹤0.01%	4044

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northwestern Mutual Wealth Management's TOVX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management opened a new position in Theriva Biologics (TOVX) in Q2 2026: 100 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #4044 among its holdings.

26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Northwestern Mutual Wealth Management held 100 shares of Theriva Biologics worth $25 as of Q2 2026.
Theriva Biologics was a new Northwestern Mutual Wealth Management position in Q2 2026.
Theriva Biologics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #4044 holding.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.